A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Study Summary

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.

Conditions

Eosinophilic Esophagitis

Interventions / Drugs

Vonoprazan Placebo

View on ClinicalTrials.gov ↗

Sponsor

PHAT

Phathom Pharmaceuticals

D41/100

Study Details

Enrollment80 participants

Primary Completion—

Lead SponsorPhathom Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:24:17.294766+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.